Company Overview and News

 
TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018

4h globenewswire
WALTHAM, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce first-quarter 2018 financial results on Thursday, May 3, 2018, after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on May 3, 2018 to discuss the Company’s operating results for the quarter in greater detail, as well as the status of its development programs.
Upvote Downvote

 
TSRO / TESARO, Inc. null

2018-04-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@
Upvote Downvote

 
BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

2018-04-16 reuters
* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:
Upvote Downvote

 
TESARO Summarizes TSR-042 Clinical Data Presented at AACR

2018-04-16 globenewswire
CHICAGO, April 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today summarized initial data from the Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody) in patients with microsatellite instability high (MSI-H) endometrial cancer and non-small cell lung cancer (NSCLC) presented during the American Association for Cancer Research (AACR) Annual Meeting.
Upvote Downvote

 
TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel

2018-04-11 globenewswire
ZUG, Switzerland and PETACH TIKVA, Israel, April 11, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Medison Pharma Ltd., Israel's leading commercial partner for innovative pharmaceuticals, today announced an exclusive distribution agreement to commercialize ZEJULA® (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, in Israel.
Upvote Downvote

 
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's Expanded Rubraca Market

2018-04-11 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

 
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy

2018-04-09 zacks
Clovis Oncology, Inc. (CLVS - Free Report) recently announced that the FDA has granted approval to label expansion of its PARP inhibitor, Rubraca (rucaparib). The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum-based chemotherapy. The drug can now also be prescribed irrespective of BRCA-mutation in the second-line setting.
Upvote Downvote

 
Reader Inquiry: Does Clovis Oncology's Expansion Approval Make It A Buy?

2018-04-08 seekingalpha
In this new series, I address stocks that ROTY members have asked about in live chat.
Upvote Downvote

2
TSRO / TESARO, Inc. DEF 14A

2018-04-06 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS
Upvote Downvote

3
Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia.
Upvote Downvote

 
U.S. Biotech/Pharma Sector Daily Observations Letter: March 26, 2018

2018-03-27 seekingalpha
The U.S. equity indexes rebounded today from key 200-day moving average support level after trade negotiations between the U.S. and China were reported.
Upvote Downvote

 
BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

2018-03-26 reuters
* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER
Upvote Downvote

 
Clovis Gets Positive CHMP Opinion for Ovarian Cancer Drug

2018-03-26 zacks
Clovis Oncology, Inc. (CLVS - Free Report) announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has issued a positive opinion recommending approval of PARP inhibitor, Rubraca (rucaparib). The company is seeking approval of the drug as monotherapy for the treatment of women with platinum-sensitive ovarian cancer with BRCA mutation.
Upvote Downvote

1
Stocks To Watch: Back To School For Apple

2018-03-24 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Upvote Downvote

 

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 881569107